Purification and Molecular Characterization of the Novel Highly Potent Bacteriocin TSU4 Produced by Lactobacillus animalis TSU4

Abstract

Bacterial infections causing fish diseases and spoilage during fish food processing and storage are major concerns in aquaculture. Use of bacteriocins has recently been considered as an effective strategy for prevention of bacterial infections. A novel bacteriocin produced by Catla catla gut isolates, Lactobacillus animalis TSU4, designated as bacteriocin TSU4 was purified to homogeneity by a three-step protocol. The molecular mass of bacteriocin TSU4 was 4117 Da determined by Q-TOF LC/MS analysis. Its isoelectric point was ~9. Secondary conformation obtained by circular dichroism spectroscopy showed molecular conformation with significant proportions of the structure in α-helix (23.7 %) and β-sheets (17.1 %). N-terminal sequencing was carried out by the Edman degradation method; partial sequence identified was NH2-SMSGFSKPHD. Bacteriocin TSU4 exhibited a wide range of antimicrobial activity, pH and thermal stability. It showed a bacteriocidal mode of action against the indicator strain Aeromonas hydrophila MTCC 646. Bacteriocin TSU4 is the first reported bacteriocin produced by fish isolate Lactobacillus animalis. The characterization of bacteriocin TSU4 suggested that it is a novel bacteriocin with potential value against infections of bacteria such as A. hydrophila MTCC 646 and Pseudomonas aeruginosa MTCC 1688 and application to prevent spoilage during food preservation.

Purification and partial characterization of antilisterial bacteriocin produced byPediococcus pentosaceusKJBC11 fromIdlibatter fermented withPiper betleleaves

“…The hydrophobic interaction chromatography performed on the re‐run gave good antilisterial activity in 10% isopropanol eluent in which the bacteriocin was found to be pure with a single peak having retention time of 15.86 min (Figure c). This strategy has been applied by many researchers to purify bacteriocins (Khochamit, Siripornadulsil, Sukon, & Siripornadulsil, ; Sahoo, Jena, Patel, & Seshadri, ; Saraiva et al, ; Sawa et al, ), however, other techniques such as fast protein liquid chromatography (FPLC) and filter assisted size exclusion protein fractionation were employed to speed up the purification of bacteriocins (Choi, Cheigh, Kim, & Pyun, ; Chumchalova, Stiles, Josephsen, & Plockova, ). The inhibitory activity, specific activity, and yield of bacteriocin KJBC11 obtained are presented in Table .…”

The Modulation Effect of Triglyceride Type and Phospholipids Type ω-3 LCPUFA on Mice Gut Microbiota

“…So we can conclude that the two types of ω-3 LCPUFA have the ability to improve Lactobacillus animalis, in previous study, which is a potent broad spectrum probiotic strain which inhibited bacterial pathogens, such as A. hydrophila, Pseudomonas aeruginosa and other food spoil pathogens. According to previous study, Lactobacillus animalis would range from preventing against human gastrointestinal bacterial pathogens [13] [14]. Akkermansia muciniphila is a mucin-degrading bacterium that resides in the mucus layer [15].…”

“…But few studies had investigated the effects of dietary lipids on human intestinal microbiota. According to some studies, dietary lipids are mostly absorbed in the small intestine, but a recent research showed that 7% of 13 C labeled dietary fatty acids were excreted in stool [11], which indicated that intestinal flora and dietary fat can interact between each other. But the effects on microbiota caused by ω-3 LCPUFA and the differences caused by triglyceride type ω-3 LCPUFA and phospholipids type ω-3 LCPUFA are not clear.…”

Mining, heterologous expression, purification, antibactericidal mechanism, and application of bacteriocins: A review

“…Those bacteria come from different sources, including meat and vegetables (Gao, Li, Liu, & Zhang, 2015; Hu et al., 2017; Rumjuankiat et al., 2015), soil (Odah et al., 2020; Qin et al., 2019), human skin (Liu et al., 2020; Lynch et al., 2019; O'Sullivan et al., 2020), animal gut (O'Connor, O'Shea, Cotter, Hill, & Ross, 2018; Sahoo, Jena, Patel, & Seshadri, 2015; Sugrue, O'Connor, Hill, Stanton, & Ross, 2020; Wayah & Philip, 2018), and human vagina (Maldonado‐Barragan, Caballero‐Guerrero, Martin, Ruiz‐Barba, & Rodriguez, 2016; Sharma, Rashid, & Kaur, 2020). Interestingly, many novel bacteriocins showed broad‐spectrum antibacterial activity (Lee & Chang, 2018; Sahoo et al., 2015; Sugrue et al., 2020). In addition, some bacteriocin expressed bacteriostatic activity to drug‐resistant bacteria, such as MRSA (Odah et al., 2020) and vancomycin‐resistant E. faecium (Liu et al., 2020).…”